ISSN 1662-4009 (online)

ey0016.5-9 | Clinical Advances in Treatment | ESPEYB16

5.9. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial

MP Whyte , JH Simmons , S Moseley , KP Fujita , N Bishop , NJ Salman , J Taylor , D Phillips , M McGinn , WH McAlister

Abstract: Lancet Diabetes Endocrinol. 2019 Feb;7(2):93–105.In brief: The study reports outcomes of a single-arm 7-year phase 2 extension trial of Asfotase alfa for infants and children with life-threatening hypophosphatasia who received a median of 6·6 years of therapy. The early improvements previously reported were sustained for up to 7 years of treatment.<p class...

ey0016.3-2 | Thyroid Hormone Action | ESPEYB16

3.2. Thyroid hormone signaling specifies cone subtypes in human retinal organoids

KC Eldred , SE Hadyniak , KA Hussey , B Brenerman , PW Zhang , X Chamling , VM Sluch , DS Welsbie , S Hattar , J Taylor , K Wahlin , DJ Zack , RJ Jr Johnston

To read the full abstract: Science. 2018;362(6411).Here, developmental regulation of deiodinases DIO2 and DIO3 were identified as main regulators of thyroid hormone dependent sequential cone subtype specification in human retinal organoids. Either complete loss of thyroid hormone signaling or non-physiologically high thyroid hormone levels completely suppressed either medium and long wav...

ey0020.1-11 | Autoimmune Thyroid Disease | ESPEYB20

1.11. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK

N Conrad , S Misra , JY Verbakel , G Verbeke , G Molenberghs , PN Taylor , J Mason , N Sattar , JJV McMurray , IB McInnes , K Khunti , G Cambridge

Brief summary: Over the last decades changing incidences for autoimmune diseases have been observed. However, no data are available so far on long-term trends, incidence over the whole age spectrum (child, adults, geriatric patients), and incidence of co-occurrence of the different autoimmune diseases. The presented study provides an extensive population-based cohort study performed in the UK.The authors used electronic health care records of 22 million ...

ey0020.3-1 | Novel Treatments for Rare Skeletal Disorders | ESPEYB20

3.1. Safety and efficacy of denosumab for fibrous dysplasia of bone

LF de Castro , Z Michel , K Pan , J Taylor , V Szymczuk , S Paravastu , B Saboury , GZ Papadakis , X Li , K Milligan , B Boyce , SM Paul , MT Collins , AM Boyce

In Brief: This phase 2 study investigated the effect of the RANKL inhibitor denosumab on fibrous dysplasia lesion activity, as well as the rebound in bone turnover after treatment discontinuation.Commentary: Denosumab is a humanized monoclonal antibody that inhibits RANKL with potent but transient antiosteoclastic effects, and discontinuation of denosumab treatment is associated with a rebound in bone turnover. In this study, eight women received high do...

ey0021.3-6 | Thyroid Function - Genetic Determinants and Associations with Health and (Thyroid) Disease | ESPEYB21

3.6. Genetic determinants of thyroid function in children

Mulder Tessa A , Campbell Purdey J , Taylor Peter N , Peeters Robin P , Wilson Scott G , Medici Marco , Dayan Colin , Jaddoe Vincent V W , Walsh John P , Martin Nicholas G , Tiemeier Henning , Korevaar Tim I M

Brief Summary: This study investigated the genetic determinants of thyroid function in newborns and (pre)school children by analyzing the associations between single nucleotide polymorphisms (SNPs) previously identified in adults, and childhood TSH within the reference interval, and FT4 concentrations. It included three large population-based cohorts with data on genetic variants and thyroid function: Generation R (Netherlands), ALSPAC (UK), and BLTS (Australia), comprising 7,...